X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the agreement, GSK has the rights to develop GSK5458448/SCY-078 (ibrexafungerp), a novel oral glucan synthase inhibitor with a broad spectrum of activity and commercialize Brexafemme (ibrexafungerp tablets) in all countries except the greater China region.
Lead Product(s): Ibrexafungerp Citrate,Caspofungin
Therapeutic Area: Infections and Infectious Diseases Product Name: GSK5458448
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: GSK
Deal Size: $401.0 million Upfront Cash: $90.0 million
Deal Type: Licensing Agreement January 03, 2024
Details:
Brexafemme (ibrexafungerp), a novel glucan synthase inhibitor, approved for vulvovaginal candidiasis and RVVC, is being develop in phase 3 trials for the potential treatment of invasive candidiasis.
Lead Product(s): Ibrexafungerp Citrate
Therapeutic Area: Infections and Infectious Diseases Product Name: Brexafemme
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Hansoh Pharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 20, 2023
Details:
Under the agreement GSK gains right to commercialize Brexafemme (ibrexafungerp), a novel glucan synthase inhibitor, for vulvovaginal candidiasis and RVVC while continuing to develop ibrexafungerp, in phase 3 trials for the potential treatment of invasive candidiasis.
Lead Product(s): Ibrexafungerp Citrate,Caspofungin
Therapeutic Area: Infections and Infectious Diseases Product Name: Brexafemme
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: GSK
Deal Size: $593.0 million Upfront Cash: $90.0 million
Deal Type: Licensing Agreement June 21, 2023
Details:
Under the agreement, GSK has the rights to develop ibrexafungerp, a novel oral glucan synthase inhibitor with a broad spectrum of activity and commercialize Brexafemme (ibrexafungerp tablets) in all countries except the greater China region.
Lead Product(s): Ibrexafungerp Citrate
Therapeutic Area: Infections and Infectious Diseases Product Name: Brexafemme
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: GSK
Deal Size: $593.0 million Upfront Cash: $90.0 million
Deal Type: Licensing Agreement May 12, 2023
Details:
Under the agreement, GSK gains rights to commercialise Brexafemme, a first-in-class antifungal for the treatment of VVC and for reduction in the incidence of RVVC while continuing to develop ibrexafungerp, which is in phase III trials for the potential treatment of IC.
Lead Product(s): Ibrexafungerp Citrate
Therapeutic Area: Infections and Infectious Diseases Product Name: Brexafemme
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: GSK
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement March 30, 2023
Details:
Brexafemme (ibrexafungerp) is a novel oral triterpenoid antifungal approved for the treatment of vulvovaginal candidiasis (VVC). Its mechanism of action, glucan synthase inhibition, is fungicidal against Candida species, meaning it kills fungal cells.
Lead Product(s): Ibrexafungerp Citrate
Therapeutic Area: Infections and Infectious Diseases Product Name: Brexafemme
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 01, 2022
Details:
NIH to investigate a second generation fungerp (SCY-247) developed by SCYNEXIS as a potential treatment for Candida auris (C.auris), a multidrug-resistant yeast that causes serious and often deadly infections.
Lead Product(s): SCY-247
Therapeutic Area: Infections and Infectious Diseases Product Name: SCY-247
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: National Institutes of Health
Deal Size: $3.0 million Upfront Cash: Undisclosed
Deal Type: Funding November 30, 2022
Details:
Brexafemme (Ibrexafungerp) is an antifungal agent and the first representative of a novel class of structurally-distinct glucan synthase inhibitors, triterpenoids.
Lead Product(s): Ibrexafungerp Citrate
Therapeutic Area: Infections and Infectious Diseases Product Name: Brexafemme
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 17, 2022
Details:
Cumulative interim analysis of outcomes by fungal disease type highlighted in a platform presentation demonstrates 82.3% positive clinical outcomes in patients treated with brexafemme (ibrexafungerp).
Lead Product(s): Ibrexafungerp Citrate
Therapeutic Area: Infections and Infectious Diseases Product Name: Brexafemme
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 24, 2022
Details:
Brexafemme (ibrexafungerp) is in late-stage development for multiple indications, including life-threatening fungal infections caused primarily by Candida (including C. auris) and Aspergillus species in hospitalized patients.
Lead Product(s): Ibrexafungerp Citrate
Therapeutic Area: Infections and Infectious Diseases Product Name: Brexafemme
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 11, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
